OHC

Oxford-Harrington Rare Disease Centre Opens Call for Proposals

Retrieved on: 
Tuesday, February 6, 2024
Partnership, Genomics, Genomics England, Access, Therapy, DSM-IV codes, OHC, University of Oxford, Intellectual property, University, Cancer, Pharmaceutical industry

OXFORD, U.K. and CLEVELAND, Feb. 6, 2024 /PRNewswire/ -- The Oxford-Harrington Rare Disease Centre (OHC), a partnership between the University of Oxford, U.K. and Harrington Discovery Institute at University Hospitals, Cleveland, Ohio, is seeking innovative projects for its 2024 Rare Disease Scholar Award, which advances promising discoveries from academic labs into clinical practice. In addition to grant funding, the award includes drug and business development support from pharma-experienced industry leaders with a track record of bringing therapeutics to market. Awardees have access to the Oxford-Harrington Rare Disease Centre Therapeutics Accelerator, which receives support from a partnership between University of Oxford, Oxford Science Enterprises, and University Hospitals in Cleveland, Ohio.

Key Points: 
  • OXFORD, U.K. and CLEVELAND, Feb. 6, 2024 /PRNewswire/ -- The Oxford-Harrington Rare Disease Centre (OHC), a partnership between the University of Oxford, U.K. and Harrington Discovery Institute at University Hospitals, Cleveland, Ohio, is seeking innovative projects for its 2024 Rare Disease Scholar Award, which advances promising discoveries from academic labs into clinical practice.
  • Awardees have access to the Oxford-Harrington Rare Disease Centre Therapeutics Accelerator, which receives support from a partnership between University of Oxford, Oxford Science Enterprises, and University Hospitals in Cleveland, Ohio.
  • The OHC's 2024 Rare Disease Scholar Award seeks novel approaches to treat rare diseases, with a focus on neurological disorders, developmental and metabolic disorders, and rare cancers.
  • Applications directed to other rare, genetic indications with a high unmet need are also of interest.

Oxford-Harrington Rare Disease Centre Opens Call for Proposals

Retrieved on: 
Tuesday, February 6, 2024
Partnership, Genomics, Genomics England, Access, Therapy, DSM-IV codes, OHC, University of Oxford, Intellectual property, University, Cancer, Pharmaceutical industry

OXFORD, U.K. and CLEVELAND, Feb. 6, 2024 /PRNewswire/ -- The Oxford-Harrington Rare Disease Centre (OHC), a partnership between the University of Oxford, U.K. and Harrington Discovery Institute at University Hospitals, Cleveland, Ohio, is seeking innovative projects for its 2024 Rare Disease Scholar Award, which advances promising discoveries from academic labs into clinical practice. In addition to grant funding, the award includes drug and business development support from pharma-experienced industry leaders with a track record of bringing therapeutics to market. Awardees have access to the Oxford-Harrington Rare Disease Centre Therapeutics Accelerator, which receives support from a partnership between University of Oxford, Oxford Science Enterprises, and University Hospitals in Cleveland, Ohio.

Key Points: 
  • OXFORD, U.K. and CLEVELAND, Feb. 6, 2024 /PRNewswire/ -- The Oxford-Harrington Rare Disease Centre (OHC), a partnership between the University of Oxford, U.K. and Harrington Discovery Institute at University Hospitals, Cleveland, Ohio, is seeking innovative projects for its 2024 Rare Disease Scholar Award, which advances promising discoveries from academic labs into clinical practice.
  • Awardees have access to the Oxford-Harrington Rare Disease Centre Therapeutics Accelerator, which receives support from a partnership between University of Oxford, Oxford Science Enterprises, and University Hospitals in Cleveland, Ohio.
  • The OHC's 2024 Rare Disease Scholar Award seeks novel approaches to treat rare diseases, with a focus on neurological disorders, developmental and metabolic disorders, and rare cancers.
  • Applications directed to other rare, genetic indications with a high unmet need are also of interest.

Automotive Dual Variable Valve Timing Market size to grow by USD 12.52 billion from 2022 to 2027, the market is fragmented due to the presence of prominent companies like AISIN CORP., BorgWarner Inc. and Cummins Inc., and many more - Technavio

Retrieved on: 
Monday, January 8, 2024
Electronic control unit, Hitachi, Mitsubishi Electric, OHC, VVT, Electric vehicle, EVS, Toyota, CVVT, Holset, BorgWarner, General Motors, Geography, USD, ECU, Ford Motor Company, RPM, Torque, Mahle GmbH, Volkswagen Group, VGT, Growth, EV

The automotive dual variable valve timing market is fragmented owing to the presence of many global and regional companies.

Key Points: 
  • The automotive dual variable valve timing market is fragmented owing to the presence of many global and regional companies.
  • Who are the key players in the Automotive Dual Variable Valve Timing Market?
  • BorgWarner Inc. - The company offers automotive dual variable valve timing such as BorgWarner VCT Technology with mid-position lock.
  • Cummins Inc. - The company offers automotive dual variable valve timing such as the Holset Variable-Geometry Turbocharger (VGT), that optimizes engine performance and fuel efficiency.

bioMérieux Canada, AMMI Canada, EPIC and AMR-One Health Consortium co-host the second Canadian symposium to fight antimicrobial resistance

Retrieved on: 
Wednesday, November 22, 2023
Ministry, EPIC, Global health, Research, Emerging, Microbiology, WHO, OHC, Risk, Disease, One Health, MaRS Discovery District, Infection, Death, Pharmacology, AMR, Diagnosis, Software, Medical microbiology, Veterinary medicine, Physician, Legislation, Public, Education, Ministry of Health, Medical device, Pharmaceutical industry, Health

This scientific summit aims to identify concrete actions to combat antimicrobial resistance while highlighting Canadian research and leadership in this crucial fight.

Key Points: 
  • This scientific summit aims to identify concrete actions to combat antimicrobial resistance while highlighting Canadian research and leadership in this crucial fight.
  • "Infectious Diseases physicians, medical microbiologists and clinical microbiologists are actively involved in research, innovation and education to combat antimicrobial resistance.
  • A One Health approach in line with the Pan-Canadian Action Plan to combat AMR is a priority"," says Dr. Deborah Yamamura, President of AMMI Canada.
  • Several discussions will also focus on the One Health approach, which, with its collaborative cross-disciplinary and cross-sector approach, is essential in the fight against antimicrobial resistance.

DHS Selects ICF for New $36 Million Digital Modernization Task Order

Retrieved on: 
Monday, November 13, 2023
WLE, ICFI, Woman, Immigration, Law enforcement, ICF, OHC, Workforce, Women in law enforcement, Human Capital, Ecosystem, IDIQ, ServiceNow, DHS, ICE, Arms industry, Management

RESTON, Va., Nov. 13, 2023 /PRNewswire/ -- The U.S. Department of Homeland Security (DHS) Office of Human Capital (OHC) recently awarded a new $36 million task order to global consulting and technology services provider ICF (NASDAQ:ICFI) to modernize the Immigration and Customs Enforcement's (ICE) human resources technology systems.

Key Points: 
  • The task order was awarded in the third quarter of 2023 under the Scalable Ways to Implement Flexible Tasks (SWIFT) indefinite-delivery, indefinite-quantity contract (IDIQ), which was awarded to ICF in fall 2022.
  • In addition to workforce and technology capabilities, ICF will also bring its DEIA organizational expertise to support this initiative.
  • ICF was also recently awarded a new $32 million ICF SWIFT task order to modernize ICE's homeland security investigations systems.
  • ICF was named ServiceNow's 2022 U.S. Federal Partner of the Year and is one of the only companies to receive this distinction twice.

The Oxford-Harrington Rare Disease Centre Launches Pioneering Therapeutics Accelerator to Advance Innovative Treatments for Rare Diseases

Retrieved on: 
Tuesday, October 3, 2023
Partnership, Disease, Drug development, University, Therapy, 100,000 Genomes Project, Rare disease, University Hospitals Cleveland Medical Center, Hope, University of Oxford, Research, Genomics, OHC, OXFORD, DSM-IV codes, Translation, Oxford Sciences Enterprises, MD, Patient, Investment, Cancer, Genomics England, Department of Biology, University of Oxford, Motivation, Accelerator, Foreign policy, Rare, Courage, Family, Harrington, Pharmaceutical industry, Hospital, Nursing, Vaccine, Management, Neuroscience, Medicine, Pediatrics

Former U.K. Prime Minister David Cameron to lead the international efforts of the Accelerator as Chair of the Oxford-Harrington Rare Disease Centre Advisory Board.

Key Points: 
  • Former U.K. Prime Minister David Cameron to lead the international efforts of the Accelerator as Chair of the Oxford-Harrington Rare Disease Centre Advisory Board.
  • The Accelerator is a first-in-kind, transatlantic initiative to identify, fund and advance breakthrough academic discoveries to deliver new treatments for the 400 million people worldwide who suffer from rare diseases.
  • The partners are also collaborating to create a dedicated Rare Disease Impact Fund to enable investments in mission-aligned projects and accelerate the development of rare disease therapeutics.
  • For academics and researchers to find out more about the Therapeutics Accelerator at the Oxford-Harrington Rare Disease Centre and how to apply, please go to OxfordHarrington.org .

The Oxford-Harrington Rare Disease Centre Launches Pioneering Therapeutics Accelerator to Advance Innovative Treatments for Rare Diseases

Retrieved on: 
Tuesday, October 3, 2023
Partnership, Disease, Drug development, University, Therapy, 100,000 Genomes Project, Rare disease, University Hospitals Cleveland Medical Center, Hope, University of Oxford, Research, Genomics, OHC, OXFORD, DSM-IV codes, Translation, Oxford Sciences Enterprises, MD, Patient, Investment, Cancer, Genomics England, Department of Biology, University of Oxford, Motivation, Accelerator, Foreign policy, Rare, Courage, Family, Harrington, Pharmaceutical industry, Hospital, Nursing, Vaccine, Management, Neuroscience, Medicine, Pediatrics

Former U.K. Prime Minister David Cameron to lead the international efforts of the Accelerator as Chair of the Oxford-Harrington Rare Disease Centre Advisory Board.

Key Points: 
  • Former U.K. Prime Minister David Cameron to lead the international efforts of the Accelerator as Chair of the Oxford-Harrington Rare Disease Centre Advisory Board.
  • The Accelerator is a first-in-kind, transatlantic initiative to identify, fund and advance breakthrough academic discoveries to deliver new treatments for the 400 million people worldwide who suffer from rare diseases.
  • The partners are also collaborating to create a dedicated Rare Disease Impact Fund to enable investments in mission-aligned projects and accelerate the development of rare disease therapeutics.
  • For academics and researchers to find out more about the Therapeutics Accelerator at the Oxford-Harrington Rare Disease Centre and how to apply, please go to OxfordHarrington.org .

U.S. Oral Surgery Management Secures $150 Million Credit Expansion

Retrieved on: 
Thursday, August 17, 2023
Partnership, PPM, Marketing, OHC, NPS, Patient, Practice management, Growth, Bain & Company, Health, Dentistry, Pharmaceutical industry, Oak Hill Capital Partners

Oral Surgery Management (USOSM), the first and largest physician practice management (PPM) company in the oral and maxillofacial surgery specialty, announced today that it has closed on a new $150 million credit expansion.

Key Points: 
  • Oral Surgery Management (USOSM), the first and largest physician practice management (PPM) company in the oral and maxillofacial surgery specialty, announced today that it has closed on a new $150 million credit expansion.
  • The funding is an expansion of USOSM’s current credit facility with its existing lenders.
  • “The credit markets continue to be more limited for PPM businesses, and not all credit is equal.
  • Our success is driven by our laser focus on oral and maxillofacial surgery and on our surgeon partners in support of their service to their patients.

OCU Health Care Inc. Launches Groundbreaking Patient Technology Solution with Kansas Medical Center

Retrieved on: 
Thursday, August 3, 2023
Hardware, Health Technology, Telemedicine, Virtual Medicine, Consumer Electronics, Other Health, Technology, Practice Management, Managed Care, General Health, Hospitals, Wearables, Mobile Technology, Other Technology, Biotechnology, Software, Health, KMC, Partnership, Education, Patient, Overalls, Research, OHC, VR, National Association Medical Staff Services, Agency for Healthcare Research and Quality, Hospital, Agency, University of Kansas Medical Center, Virtual reality, AHRQ, Nursing

Ocu Health Care (OHC) Inc., is thrilled to announce the launch of its groundbreaking platform aimed at revolutionizing healthcare, reducing costs, and delivering better patient outcomes through tailored educational programs prior to discharge.

Key Points: 
  • Ocu Health Care (OHC) Inc., is thrilled to announce the launch of its groundbreaking platform aimed at revolutionizing healthcare, reducing costs, and delivering better patient outcomes through tailored educational programs prior to discharge.
  • OHC is partnering with Kansas Medical Center, in its effort to provide a select group of patients with technology products that deliver education with a low-stress experience through VR headsets.
  • “We’re collecting insightful feedback and patient data to tap into innovative ways to continue refining this technology and introduce Ocu Health Care as a valuable resource for patients and medical professionals nationwide,” Darkazanli said.
  • To learn more about Ocu Health Care, please visit us at www.ocuhealthcare.com or reach out to Ammar Darkazanli at [email protected] regarding investment opportunities.

HUD SECRETARY FUDGE REITERATES COMMITMENT TO END APPRAISAL BIAS AND CREATE HOUSING OPPORTUNITIES IN MARGINALIZED COMMUNITIES

Retrieved on: 
Thursday, August 3, 2023
Online, WE, Black and Brown!, Fair Housing Assistance Program, Housing, Privacy Office of the U.S. Department of Homeland Security, Education, Speech, White House Counsel, Estate agent, National Association of Real Estate Brokers, Fair Housing Initiatives Program, United States Secretary of Housing and Urban Development, Policy, OH, HUD, OHC, NAREB, FHA, National Association, Bias, White, Counselor, Real estate, Renewable energy, Black

HOUSTON, Aug. 3, 2023 /PRNewswire/ -- The National Association of Real Estate Brokers (NAREB) agreed yesterday to work with the U.S. Department of Housing and Urban Development (HUD) to address appraisal bias and discrimination through education, outreach, and other activities.

Key Points: 
  • "HUD and NAREB will work together to fight appraisal bias in the Black community," said Secretary Marcia L. Fudge in a dynamic and inspirational address that ignited passion and commitment among attendees at NAREB's annual convention.
  • Secretary Fudge added that the commitment to tackling appraisal bias reflects the administration's dedication to promoting fairness in housing valuations and bringing equity to all communities.
  • Specifically, the agreement with HUD cites several collaborative actions in the fiscal year 2024, which begins October 1, 2023:
    Online training opportunities for housing counselors to understand racial appraisal bias in home property valuation.
  • Secretary Fudge fired up the audience with her powerful commitment to addressing racial disparities in housing for marginalized communities.